Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders

• DOI: 10.1016/j.xcrm.2022.100607
• Publication Date: 2022-04-19T15:22:22Z
• Authors: Tania F. Gendron; Michael G. Heckman; Launia J. White; Austin M. Veire; Otto Pedraza; Alexander R. Burch; Andrea C. Bozoki; Bradford C. Dicke...; Kimiko Domoto-Reilly; Tatiana Foroud; Leah K. Forsberg; Douglas R. Galasko; Nupur Ghoshal; Neill R. Graff-Ra...; Murray Grossman; Hilary W. Heuer; Edward D. Huey; Ging-Yuek R. Hsiung; David J. Irwin; Daniel I. Kaufer; Gabriel C. Leger; Irene Litvan; Joseph C. Masdeu; Mario F. Mendez; Chiadi U. Onyike; Belen Pascual; Aaron Ritter; Erik D. Roberson; Julio C. Rojas; Maria Carmela Tar...; Zbigniew K. Wszolek; Howard Rosen; Bradley F. Boeve; Adam L. Boxer; Leonard Petrucelli; Brian S. Appleby; Sami Barmada; Yvette Bordelon; Hugo Botha; Danielle Brushaber; David Clark; Giovanni Coppola; Ryan Darby; Katrina Devick; Dennis Dickson; Kelley Faber; Anne Fagan; Julie A. Fields; Ralitza Gavrilova; Daniel Geschwind; Jill Goldman; Jonathon Graff-Ra...; Ian Grant; David T. Jones; Kejal Kantarci; Diana Kerwin; David S. Knopman; John Kornak; Walter Kremers; Maria Lapid; Argentina Lario Lago; Peter Ljubenkov; Diane Lucente; Ian R. Mackenzie; Scott McGinnis; Carly Mester; Bruce L. Miller; Peter Pressman; Rosa Rademakers; Vijay K. Ramanan; E. Marisa Ramos; Katherine P. Rankin; Meghana Rao; Katya Rascovsky; Rodolfo Savica; William Seeley; Adam M. Staffaroni; Jeremy Syrjanen; Jack Taylor; Lawren VandeVrede; Sandra Weintraub; Bonnie Wong
• Keywords: Frontotemporal lobar degeneration; Selegiline

Frontotemporal dementia (FTD) therapy development is hamstrung by a lack of susceptibility, diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows promise as biomarker, but studies have largely focused only on core FTD syndromes, often grouping patients with different diagnoses. To expedite the clinical translation NfL, we avail ARTFL LEFFTDS Longitudinal Lobar Degeneration (ALLFTD) study resources conduct comprehensive investigation plasma NfL across syndromes in presymptomatic mutation carriers. We find elevated all studied including mild cases; increases carriers prior to phenoconversion; associates indicators disease severity. By facilitating identification individuals at risk phenoconversion, early diagnosis FTD, can aid participant selection for prevention or treatment trials. Moreover, its utility would improve patient care, trial efficiency, outcome estimations.